Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesInhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
87.1 USD -3.49 ( 3.85%)
Last update at 2026-11-12T15:27:00Z
VOLUME
20464
Market Cap
1554.33M

Momentum Score

…

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
86.00
Low
88.56
High
52 Week Price Range
26.20
Low
155.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing engineered protein therapeutics with programs in oncology and other serious diseases. Long-term growth may be driven by clinical trial progress, strategic partnerships and eventual regulatory approvals, supported by proprietary discovery and engineering capabilities. Investors may find the company attractive for a diversified, platform-enabled pipeline and the potential for high-value clinical milestones.
Material risks include high clinical and regulatory execution risk, binary trial outcomes, limited commercial history and likely need for additional capital to fund development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
90.59
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-103.00M
Debt / Equity
13.39
ROE
-1773.60%
Net Debt
-17.21M
ROCE
-113.47%
Diluted EPS TTM
-8.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -140.05M 1687.57M -239.72M -145.22M -81.77M
Net income -140.06M 1687.57M -241.36M -145.23M -81.77M
Selling general administrative 23.30M 127.91M 29.38M 21.12M 12.36M
Gross profit -1.18M -2.08M 0.61M 2.18M 7.12M
Reconciled depreciation 2.48M 2.29M 1.19M 1.23M 1.20M
Ebit -127.86M 1701.07M -207.88M -130.34M -77.76M
Ebitda -125.37M 1703.35M -206.69M -129.12M -76.56M
Depreciation and amortization 2.48M 2.29M 1.19M 1.23M 1.20M
Non operating income net other - - - 0.00M 0.01M
Operating income -135.03M -331.45M -219.22M -129.12M -76.56M
Other operating expenses 136.32M 331.65M 221.02M 131.29M 83.69M
Interest expense 12.20M 13.49M 31.84M 16.11M 5.22M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 7.55M 10.94M 11.92M - -
Net interest income -4.65M -2.55M -19.92M -16.11M -5.22M
Income tax expense 0.00M 0.00M 0.00M 0.00M 0.00M
Total revenue 1.30M 0.20M 1.80M 2.18M 7.12M
Total operating expenses 133.84M 329.36M 219.83M 131.29M 83.69M
Cost of revenue 2.48M 2.29M 1.19M - -
Total other income expense net -5.03M 2019.02M -20.50M -16.11M -5.20M
Net income from continuing ops -140.06M 1687.57M -241.36M -145.23M -81.77M
Net income applicable to common shares - - - -145.23M -81.77M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 146.48M 180.77M 307.89M 290.88M 150.45M
Other current assets 8.43M 7.38M 16.66M 6.63M 7.81M
Total liab 138.49M 47.18M 264.39M 232.82M 98.07M
Total stockholder equity 7.99M 133.58M 43.50M 58.06M 52.38M
Other current liab 25.53M 29.89M 43.30M 17.22M 9.62M
Common stock 0.00M 0.00M 0.01M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.01M 0.00M 0.00M
Retained earnings -246.19M -106.13M -613.73M -372.37M -227.15M
Other liab - - - - 0.11M
Other assets - - 0.00M 3.16M 1.85M
Cash 124.22M 152.60M 277.92M 273.87M 131.30M
Total current liabilities 33.80M 40.73M 56.31M 27.58M 22.45M
Current deferred revenue - - - 0.17M 2.03M
Net debt -17.21M -144.55M -67.78M -71.80M -60.83M
Short term debt 2.33M 1.59M 2.06M 1.86M 1.67M
Short long term debt total 107.01M 8.05M 210.14M 202.07M 70.47M
Other stockholder equity 254.18M 239.72M 657.23M 430.43M 279.53M
Property plant equipment - - - 2.50M 9.49M
Total current assets 132.83M 160.40M 295.36M 280.49M 139.11M
Net tangible assets - - - 58.06M 52.38M
Net receivables 0.18M 0.42M 0.78M 0.26M 0.88M
Long term debt 100.56M - 206.97M 202.07M 70.47M
Inventory - - - -0.26M -0.88M
Accounts payable 5.94M 9.24M 10.95M 8.33M 9.12M
Accumulated other comprehensive income - - 0.00M - -150.45M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -372.37M -227.15M
Non currrent assets other 4.38M 6.83M 3.16M 3.16M 1.85M
Non current assets total 13.65M 20.37M 12.53M 10.38M 11.34M
Capital lease obligations 6.45M 8.05M 3.17M 5.03M 6.71M
Long term debt total - - - 202.07M 70.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.60M -4.59M -0.69M -0.81M
Change to liabilities - - - 6.90M -6.32M
Total cashflows from investing activities -0.03M -2.60M -4.59M -0.69M -0.81M
Net borrowings 99.97M 0.00M - 128.86M 39.99M
Total cash from financing activities 101.45M 71.68M 201.96M 258.55M 83.77M
Change to operating activities - - - 5.71M -11.03M
Net income -140.06M 1687.57M -239.73M -145.23M -81.77M
Change in cash -28.38M -125.33M 4.06M 142.56M 2.64M
Begin period cash flow 152.60M 277.92M 273.87M 131.30M 128.66M
End period cash flow 124.22M 152.60M 277.92M 273.87M 131.30M
Total cash from operating activities -129.79M -194.41M -193.31M -115.30M -80.32M
Issuance of capital stock - 0.00M 200.00M 127.37M 40.20M
Depreciation 2.48M 2.29M 1.19M 1.23M 1.20M
Other cashflows from investing activities - - - - 0.06M
Change to inventory - - - - -11.03M
Change to account receivables 0.24M 0.38M -0.52M 0.13M -0.17M
Sale purchase of stock - - - 129.74M 43.78M
Other cashflows from financing activities - 71.68M 201.96M 131.18M 43.57M
Change to netincome - - - 20.47M 16.53M
Capital expenditures 0.03M 2.60M 4.59M 0.69M 0.86M
Change receivables - - - 0.62M -0.14M
Cash flows other operating - - - -2.74M -7.33M
Cash and cash equivalents changes - - - 142.56M 2.64M
Change in working capital -7.61M 52.05M 15.35M 3.16M -17.52M
Stock based compensation 11.14M 58.52M 24.85M 20.45M 15.05M
Other non cash items 4.25M -1994.84M 5.03M 5.09M 2.73M
Free cash flow -129.82M -197.01M -197.90M -115.99M -81.19M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INBX
Inhibrx Biosciences, Inc.		 -3.49
3.85%		 87.10 - - 1000.46 212.28 1128.34 0.02
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

858 795 4220

https://inhibrx.com

109

Name Title Year Born
Mr. Mark Paul Lappe Founder, Chairman, Pres & CEO 1967
Dr. Brendan P. Eckelman Ph.D. Founder & Chief Scientific Officer 1979
Ms. Kelly Devine Deck B.S., CPA, M.S. Chief Financial Officer 1980
Mr. Quinn L. Deveraux Founder NA
Dr. Ashraf Amanullah Exec. VP & Chief Technical Operations Officer 1968
Ms. Leah Pollema J.D. VP, Corp. Sec. & Gen. Counsel NA
Mr. Jeffrey J. Jensen EVP & Chief Clinical Devel. Officer NA
Mr. David Matly M.B.A. Exec. VP & Chief Commercial Officer NA
Dr. Carlos Bais Ph.D. Exec. VP of Translational Sciences NA
Mr. Mark Paul Lappe Founder, Chairman, President & CEO 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…